高脂血症与血浆miRNA-365表达水平的关系

发布时间：2018-02-20 06:42

本文关键词： 高脂血症血浆 miRNA 阿托伐他汀钙　出处：《大连医科大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的:近年来,我国心血管疾病死亡占城乡居民总死亡原因的首位,其中冠状动脉粥样硬化性心脏病(简称冠心病)占了很大的比例,严重威胁我国人民的身体健康。在我国心血管疾病的危险因素如肥胖、糖尿病、高脂血症等流行趋势较为明显,导致我国心血管疾病的发病人数持续增加。高脂血症被认为是促进冠状动脉粥样硬化发生和发展的主要因素。micro RNA(简称mi RNA)是在真核细胞生物中发现的一类高度保守的具有调控功能的非编码RNA,其长度约为18-25个核苷酸。大量研究证实,mi RNA参与了包括细胞增殖、细胞凋亡、淋巴细胞的分化、器官形成、脂质代谢的调节途径。先前有学者研究发现包括肿瘤、动脉粥样硬化、高血压病、高脂血症等患者的外周循环血液中的一种或几种mi RNA与正常人表达存在明显的差异。mi RNA-365已经被证实在人脐静脉内皮细胞中参与调控氧化低密度脂蛋白诱导内皮细胞凋亡,整个过程通过mi RNA-365调节B淋巴细胞瘤-2基因来完成。本研究我们通过荧光定量PCR技术来测量高脂血症患者和正常对照组血浆中mi RNA-365的表达水平,同时我们也会进一步分析样本血浆中mi RNA-365的表达水平与不同血脂类型的关系。方法:本次研究共入选了15例高脂血症患者组和10例健康对照组。所有的研究对象在参加研究前都阅读并签署了知情同意书。所有的入选者年龄均在40岁到60岁之间。高脂血症患者入选标准:符合2007年中国成人血脂异常防治指南诊断分类标准。定义为总胆固醇(TC)≥6.22 mmol/L(240mg/dl);甘油三酯(TG)≥2.26 mmol/L(200mg/dl);低密度脂蛋白胆固醇(LDL-C)≥4.14mmol/L(160mg/dl)。排除标准:(1)经过询问病史、体格检查以及必要的实验室检查证实为肿瘤、肝功能不全、肾功能不全、肝炎、冠状动脉粥样硬化性心脏病、心肌病、先天性心脏病以及糖尿病患者。(2)不能耐受或者不适合服用阿托伐他汀钙(立普妥)患者。(3)曾接受系统降脂治疗的患者。所有入选的高脂血症患者将会重新检测血脂水平,并抽取2m L抗凝血用来提取mi RNA。高脂血症患者接受系统的降脂治疗,具体的降脂治疗方案为:每晚服用阿托伐他汀钙(立普妥)20mg,持续一个月。在服药前对入选高脂血症患者进行相关的健康教育。所有的高脂血症入选者在接受系统规范的降脂治疗后,再次检测血脂水平,并抽取2m L抗凝血用来提取mi RNA进行分析。我们从受试者血浆中提取mi RNA,通过反转录反应、荧光定量PCR扩增反应来检测血浆中mi RNA-365表达水平。所得数据计量资料均以均数±标准差的形式表示。我们应用t检验比较数据间的差异。我们应用皮尔逊相关性检验进行相关性的检查。以P≤0.05为有统计学差异。结果:1.在15例未接受系统降脂治疗的高脂血症患者的血浆中mi RNA-365的表达水平明显高于10例正常对照组血浆中mi RNA-365的表达水平(分别为7.26±3.74:0.23±0.20,P=0.001)。与此同时接受一个月系统降脂治疗后,15例高脂血症患者的血浆中mi RNA-365的表达水平仍然高于10例正常对照组血浆中mi RNA-365的表达水平(分别为2.50±1.65:0.23±0.20,P=0.002)。2.在接受一个月阿托伐他汀钙降脂治疗后,高脂血症患者血浆中mi RNA-365表达水平下降(分别为7.26±3.74:2.50±1.65,P=0.001)。3.未经过系统降脂治疗的高脂血症患者血浆中mi RNA-365含量与该患者的总胆固醇表达水平密切相关(r=0.879,P0.001)。未经过系统降脂治疗的高脂血症患者血浆中mi RNA-365含量与该患者的低密度脂蛋白胆固醇表达水平密切相关(r=0.788,P0.001)。结论:我们研究结果表明在高脂血症患者的血浆中mi RNA-365的表达水平明显高于正常对照组血浆中mi RNA-365的表达水平。在接受降脂治疗后,高脂血症患者血浆中mi RNA-365表达水平下降。未经过系统降脂治疗的高脂血症患者血浆中mi RNA含量与该患者的总胆固醇和低密度表达水平密切相关。虽然整个研究的样本量比较小,研究结果显示血浆中的mi RNA-365可能参与了高脂血症的病理过程,成为高脂血症的生物学标志物以及协助评价高脂血症患者降脂治疗的效果。
[Abstract]:Objective: in recent years, the reason for the urban and rural residents died of cardiovascular disease in our country the first death, including coronary heart disease (CHD) accounted for a large proportion in our country, a serious threat to the health of the people. At the risk of cardiovascular disease in our country because of factors such as obesity, diabetes, hyperlipidemia and other trends obviously, leading to incidence of cardiovascular disease in our country is increasing. Hyperlipidemia is considered to be the main factors to promote coronary atherosclerosis occurrence and development of.Micro RNA (MI RNA) is a kind of found in eukaryotes in the highly conserved non encoding RNA with regulatory function, its length is about 18-25 nucleotide. A number of studies have demonstrated that MI RNA is involved in including cell proliferation, apoptosis, cell differentiation, organ formation, regulation of lipid metabolism. Previous studies demonstrated that Including cancer, atherosclerosis, hypertension, one or several MI with normal RNA expression differences.Mi RNA-365 has been confirmed to be involved in regulation of oxidized low density lipoprotein induced apoptosis of endothelial cells in human umbilical vein endothelial cells in peripheral blood of patients with hyperlipidemia, the whole process of regulatory B cells the MI RNA-365 -2 gene to tumor. In this study we through fluorescence quantitative PCR technique to measure the hyperlipidemia patients and normal control group the expression level of MI in the plasma of RNA-365 at the same time, we will further analyze the relationship between the expression level of MI RNA-365 in plasma samples with different blood types. Methods: This study was selected. 15 cases of hyperlipidemia patients and 10 healthy controls. All subjects participated in the study before they read and signed the informed consent. All subjects were age Between 40 and 60 years old. Hyperlipidemia were included with the 2007 China adult dyslipidemia prevention guidelines for diagnosis classification. Defined as the total cholesterol (TC) = 6.22 mmol/L (240mg/dl); triglyceride (TG) = 2.26 mmol/L (200mg/dl); low density lipoprotein cholesterol (LDL-C) = 4.14mmol/L (160mg/dl). Exclusion criteria: (1) through the history, physical examination and laboratory tests necessary to confirm the tumor, liver dysfunction, renal insufficiency, hepatitis, coronary heart disease, cardiomyopathy, congenital heart disease and diabetes. (2) can not be tolerated or not suitable for taking atorvastatin calcium (Li Putuo). (3) patients had received lipid-lowering therapy. All patients system selected patients with hyperlipidemia and lipid levels will be re detection, extraction 2m L anticoagulant used to extract mi RNA. of hyperlipidemia received lipid-lowering treatment system Specific therapy, lipid-lowering therapy: every night to take atorvastatin (Lipitor) 20mg, lasting a month. Before taking the medicine for health education related to selected patients with hyperlipidemia hyperlipidemia. All enrolled in lipid-lowering therapy accept system specification, again detected serum lipid levels, and extract 2m L mi RNA is used to extract anti coagulation were analyzed. We extract mi RNA from serum subjects, through reverse transcription reaction, fluorescence quantitative PCR amplification to detect mi RNA-365 expression level in plasma. The data of measurement data were expressed as mean + standard deviation form. We used t test to compare the differences between data we used Pearson correlation. Correlation test. To check for P = 0.05, there was statistically significant difference. Results: 1. the expression level in 15 cases of patients with hyperlipidemia system did not receive lipid-lowering therapy in plasma mi RNA-365 Ming The expression level was higher than that of 10 cases of normal control group, plasma mi RNA-365 (7.26 + 3.74:0.23 + 0.20, P=0.001). At the same time to accept a month system of lipid-lowering therapy, the expression level of 15 cases of patients with hyperlipidemia in plasma mi RNA-365 is still higher than the expression level of 10 cases of normal control group. Plasma mi RNA-365 (2.50 + 1.65:0.23 + 0.20, P=0.002).2. in a month of atorvastatin lipid-lowering treatment, MI decreased RNA-365 levels in plasma of patients with hyperlipidemia (7.26 + 3.74:2.50 + 1.65, P=0.001).3. without mi RNA-365 in plasma of patients with hyperlipidemia lipid-lowering therapy in the system and the expression levels of total cholesterol were closely related (r=0.879, P0.001). After MI plasma RNA-365 content in patients with hyperlipidemia and lipid lowering therapy in the system with low density lipoprotein cholesterol level was closely related to Close (r=0.788, P0.001). Conclusion: the results of our study showed that the expression level of MI RNA-365 was significantly higher than the normal control group, the expression level of MI in the plasma of RNA-365 in patients with hyperlipidemia in plasma. On lipid-lowering treatment, MI decreased RNA-365 levels in plasma of patients with hyperlipidemia. After Mi plasma RNA content high hyperlipidemia patients system lipid-lowering therapy is closely related to the patients with total cholesterol and low density levels. Although the sample size of the study is relatively small, the results showed that plasma mi RNA-365 may be involved in the pathogenesis of hyperlipidemia, hyperlipidemia become biological markers and effect evaluation to assist high fat in patients with lipid-lowering therapy.

【学位授予单位】：大连医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R589.2

【相似文献】